Advertisement
YOU ARE HERE: LAT HomeCollectionsIsis Pharmaceuticals Inc
IN THE NEWS

Isis Pharmaceuticals Inc

FEATURED ARTICLES
BUSINESS
September 28, 2007 | From Times Wire Services
Isis Pharmaceuticals Inc. has acquired all outstanding shares of Symphony GenIsis for $120 million in cash and stock. Isis also reacquired full ownership of its cholesterol-lowering drug Isis 301012, the Carlsbad, Calif., company said. Symphony GenIsis was formed in April 2006 by Symphony Capital Partners to fund development of three Isis drugs.
ARTICLES BY DATE
BUSINESS
September 28, 2007 | From Times Wire Services
Isis Pharmaceuticals Inc. has acquired all outstanding shares of Symphony GenIsis for $120 million in cash and stock. Isis also reacquired full ownership of its cholesterol-lowering drug Isis 301012, the Carlsbad, Calif., company said. Symphony GenIsis was formed in April 2006 by Symphony Capital Partners to fund development of three Isis drugs.
Advertisement
BUSINESS
September 17, 2002 | Bloomberg News
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research. Terms weren't disclosed. Isis said it granted licenses for certain patents to Sequitur, which agreed to make payments to Isis and limit the types of chemistry, called antisense, it can use in research. Isis had claimed that Sequitur was using Isis technology without permission.
BUSINESS
September 14, 2007 | From Times Wire Reports
Johnson & Johnson will pay Isis Pharmaceuticals Inc. about $275 million to develop two drugs for diabetes, Isis said. Carlsbad-based Isis will initially receive $45 million, and may be paid $230 million or more for meeting milestones for the as-yet unnamed medicines.
BUSINESS
September 14, 2007 | From Times Wire Reports
Johnson & Johnson will pay Isis Pharmaceuticals Inc. about $275 million to develop two drugs for diabetes, Isis said. Carlsbad-based Isis will initially receive $45 million, and may be paid $230 million or more for meeting milestones for the as-yet unnamed medicines.
BUSINESS
December 3, 2004 | From Bloomberg News
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn's disease in two late-stage trials. The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies. Isis shares rose $1.09 to $6.01 on Nasdaq.
BUSINESS
August 28, 1998 | Washington Post
Isis Pharmaceuticals Inc. of Carlsbad has won approval to sell the first of a new kind of drug that treats disease by switching off genes. The drug, Vitravene, slows down a serious eye infection that can blind people with AIDS. The approval by the Food and Drug Administration cheered researchers who have spent three decades trying to prove that such treatments were possible.
BUSINESS
January 11, 2005 | From Bloomberg News
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment. Writing down the value of assets such as equipment and patents will cost the company as much as $40 million in the fourth quarter. Additional expenses related to the firings will be recorded in the first quarter, Carlsbad, Calif.-based Isis said, without giving a specific figure.
BUSINESS
January 6, 2004 | From Bloomberg News
Isis Pharmaceuticals Inc., which is developing drugs for cancer and autoimmune diseases, said Monday that an experimental medicine eased patients' rheumatoid arthritis symptoms in a study. The Carlsbad, Calif., company said 41% of patients who received the treatment had a measurable improvement. Rheumatoid arthritis is a crippling form of the joint disease, which primarily afflicts women. If approved, the medicine, known as Isis 104838, would compete against Amgen Inc.'
BUSINESS
March 18, 2003 | Denise Gellene, Times Staff Writer
In a stunning setback, Isis Pharmaceuticals Inc. of Carlsbad, Calif., said its leading drug candidate -- a novel therapy for lung cancer -- failed in a closely watched test of 616 patients. Company executives said they were surprised by the results because earlier human tests seemed to show that the experimental biotech medication, Affinitak, would prolong patients' lives. Lung cancer affects more than 1 million people worldwide.
BUSINESS
January 11, 2005 | From Bloomberg News
Isis Pharmaceuticals Inc. said Monday it planned to eliminate about 40% of its jobs to pare expenses and focus on developing a few key drugs, including an ulcerative colitis treatment. Writing down the value of assets such as equipment and patents will cost the company as much as $40 million in the fourth quarter. Additional expenses related to the firings will be recorded in the first quarter, Carlsbad, Calif.-based Isis said, without giving a specific figure.
BUSINESS
December 3, 2004 | From Bloomberg News
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn's disease in two late-stage trials. The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies. Isis shares rose $1.09 to $6.01 on Nasdaq.
BUSINESS
January 6, 2004 | From Bloomberg News
Isis Pharmaceuticals Inc., which is developing drugs for cancer and autoimmune diseases, said Monday that an experimental medicine eased patients' rheumatoid arthritis symptoms in a study. The Carlsbad, Calif., company said 41% of patients who received the treatment had a measurable improvement. Rheumatoid arthritis is a crippling form of the joint disease, which primarily afflicts women. If approved, the medicine, known as Isis 104838, would compete against Amgen Inc.'
BUSINESS
March 18, 2003 | Denise Gellene, Times Staff Writer
In a stunning setback, Isis Pharmaceuticals Inc. of Carlsbad, Calif., said its leading drug candidate -- a novel therapy for lung cancer -- failed in a closely watched test of 616 patients. Company executives said they were surprised by the results because earlier human tests seemed to show that the experimental biotech medication, Affinitak, would prolong patients' lives. Lung cancer affects more than 1 million people worldwide.
BUSINESS
September 17, 2002 | Bloomberg News
Isis Pharmaceuticals Inc. said it and rival Sequitur Inc. have settled three patent infringement lawsuits involving biotechnology research. Terms weren't disclosed. Isis said it granted licenses for certain patents to Sequitur, which agreed to make payments to Isis and limit the types of chemistry, called antisense, it can use in research. Isis had claimed that Sequitur was using Isis technology without permission.
BUSINESS
August 28, 1998 | Washington Post
Isis Pharmaceuticals Inc. of Carlsbad has won approval to sell the first of a new kind of drug that treats disease by switching off genes. The drug, Vitravene, slows down a serious eye infection that can blind people with AIDS. The approval by the Food and Drug Administration cheered researchers who have spent three decades trying to prove that such treatments were possible.
BUSINESS
June 6, 2003
* Isis Pharmaceuticals Inc., a Carlsbad drug developer whose experimental cancer medication failed in a study, said partner Eli Lilly & Co. waived repayment of the $21-million loan used to build the manufacturing facility for the drug.
BUSINESS
September 8, 2007 | From Times Wire Services
Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. have formed a venture uniting Nobel Prize winners David Baltimore and Phillip Sharp to create drugs from a newly discovered class of genetic material. The venture, Regulus Therapeutics, will have exclusive licenses from Alnylam and Isis for technology focused on so-called microRNAs. The molecules regulate networks of genes that may be involved in diseases including cancer, viral infections and metabolic disorders, the companies said.
Los Angeles Times Articles
|